25 March 2020
Botanix announces top line BTX 1204 atopic dermatitis data
• BTX 1204 did not achieve statistical significance in the primary and secondary endpoints in its
Phase 2 atopic dermatitis study
• Botanix will be finalising a comprehensive review of the study data and will provide an update
on the BTX 1204 program and its broader dermatology platform
Philadelphia PA and Sydney Australia, 25 March 2020: Clinical stage synthetic cannabinoid company
Botanix Pharmaceuticals Limited (ASX:BOT, “Botanix” or “the Company”) today announced that BTX
1204 did not meet the primary endpoint in its Phase 2 study evaluating the safety and efficacy in
patients with moderate atopic dermatitis (“1204 Study”).
Sad
- Forums
- ASX - By Stock
- BOT
- Ann: Antimicrobial Platform Update and Launch of BTX 1801 Study
Ann: Antimicrobial Platform Update and Launch of BTX 1801 Study, page-79
Featured News
Add BOT (ASX) to my watchlist
|
|||||
Last
41.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $752.8M |
Open | High | Low | Value | Volume |
41.0¢ | 43.5¢ | 41.0¢ | $2.989M | 7.071M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 408524 | 41.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
42.0¢ | 30000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 359035 | 0.415 |
6 | 383895 | 0.410 |
8 | 528535 | 0.405 |
12 | 590183 | 0.400 |
7 | 403387 | 0.395 |
Price($) | Vol. | No. |
---|---|---|
0.420 | 30000 | 1 |
0.425 | 136193 | 1 |
0.430 | 190093 | 5 |
0.435 | 26426 | 1 |
0.440 | 250447 | 8 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |